Craft

Antibe Therapeutics

Stock Price

$3.7

2021-01-28

Market Capitalization

$156.1 M

2021-01-28

Revenue

$7 M

FY, 2023

Antibe Therapeutics Summary

Company Summary

Overview
Antibe Therapeutics is a biotechnology company that specializes in the treatment of pain and inflammation. Its drug pipeline addresses markets in non-addictive management of chronic and post-surgical pain. The company also develops a gastrointestinal-safe anti-thrombotic medication for cardiovascular protection.
Type
Public
Status
Active
Founded
2009
HQ
Toronto, CA | view all locations
Website
https://antibethera.com/
Cybersecurity rating
Sectors

Key People

  • Amal Khouri, Director

    • Walt MacNee, Chair, Director

      • John L. Wallace, Founder, Chief Scientific Officer & Director

        • Yung Wu, Director

          LocationsView all

          1 location detected

          • Toronto, ON HQ

            Canada

            15 Prince Arthur Ave

          Antibe Therapeutics Financials

          Summary Financials

          Net income (Q3, 2024)
          ($C4.2M)
          Cash (Q3, 2024)
          $C11.3M
          EBIT (Q3, 2024)
          ($C4.6M)
          Enterprise value
          $144.8M

          Footer menu